The large number of emerging antibody-drug conjugates (ADCs) for cancer therapy has resulted in a significant market ‘boom’, garnering worldwide attention. Despite ADCs presenting huge challenges to researchers, particularly regarding the identification of a suitable combination of antibody, linker, and payload, as of September 2021, 11 ADCs have been granted FDA approval, with eight of these approved since 2017 alone. Optimism for this therapeutic approach is clear, despite the COVID-19 pandemic, 2020 was a landmark year for deals and partnerships in the ADC arena, suggesting that there remains significant interest from Big Pharma. Herein we review the enthusiasm for ADCs by focusing on the features of those approved by the FDA, and offer some thoughts as to where the field is headed.

中文翻译：

---

深入了解 FDA 批准的用于癌症治疗的抗体药物偶联物

大量新兴的用于癌症治疗的抗体药物偶联物 (ADC) 导致了显着的市场“繁荣”，引起了全世界的关注。尽管 ADC 给研究人员带来了巨大挑战，尤其是在确定抗体、接头和有效载荷的合适组合方面，但截至 2021 年 9 月，已有 11 种 ADC 获得了 FDA 的批准，其中 8 种仅自 2017 年以来就获得批准。尽管 COVID-19 大流行，但对这种治疗方法的乐观情绪是显而易见的，2020 年对于 ADC 领域的交易和合作伙伴关系来说是具有里程碑意义的一年，这表明大型制药公司仍然有浓厚的兴趣。在此，我们通过关注 FDA 批准的 ADC 的特性来回顾对 ADC 的热情，并就该领域的发展方向提供一些想法。